Table 1 Model inputs
Predialysis value (95% CI) | Dialysis value (95% CI) | ||
|---|---|---|---|
Average patient age | 60 years | ||
Gender | 60% male | ||
Renal disease origin | 20% diabetes, 17% hypertension/renal vascular disease, 15% glomerulonephritis, 48% other cause | ||
Target SP levels | <4.6 mg/dL [3] | ||
Initiation SP levels | >4.6 mg/dL [19] | >5.5 mg/dL [20] | |
Drug efficacy | |||
Response rate to CB | 44.5% (32.1-57.1) [21] | 34.1%(31.0-37.4) [22] | |
Response rate to LC | 38.3% (32.7-44.0) [19] | 16.6% (13.5-19.9) [22] | |
Drug dosage | |||
CC | 3,000 mg/day | 1,500 mg/day | |
CA | 5,000 mg/day | 3,000 mg/day | |
LC | 1,875 mg/day | 2,250 mg/day | |
Baseline yearly mortality | 12.3% [16] | ||
CKD baseline yearly progression 14.3% (13.6-15.0) [19] | |||
RR of mortality by SP level | For SA only | ||
<2.5 mg/dL | 0.95 (0.69-1.32) [17] | 1.00 (0.96-1.24) [18] | 1.00 (0.87-1.15) |
2.5 mg/dL-3.0 mg/dL | 1.00 (1.00-1.00) [17] | 1.00 (0.96-1.24) [18] | 1.00 (0.87-1.15) |
3.0 mg/dL-3.5 mg/dL | 1.15 (0.95-1.39) [17] | 1.00 (0.93-1.07) [18] | 1.00 (0.87-1.15) |
3.5 mg/dL-4.0 mg/dL | 1.32 (1.09-1.61) [17] | 1.00 (0.93-1.07) [18] | 1.00 (0.87-1.15) |
4.0 mg/dL-4.5 mg/dL | 1.34 (1.05-1.71) [17] | 1.00 (1.00-1.00) [18] | 1.00 (0.87-1.15) |
4.5 mg/dL-5.0 mg/dL | 1.83 (1.33-2.51) [17] | 1.00 (1.00-1.00) [18] | 1.00 (1.00-1.00) |
5.0 mg/dL-5.5 mg/dL | 1.90 (1.30-2.79) [17] | 1.07 (1.01-1.14) [18] | 1.00 (1.00-1.00) |
5.5 mg/dL-6.0 mg/dL | 1.90 (1.10-1.29) [17] | 1.07 (1.01-1.14) [18] | 1.02 (0.89-1.17)‡ |
6.0 mg/dL-7.0 mg/dL | 1.90 (1.10-1.29) [17] | 1.25 (1.17-1.34) [18] | |
7.0 mg/dL-8.0 mg/dL | 1.90 (1.10-1.29) [17] | 1.43 (1.31-1.54) [18] | 1.18 (1.02-1.36)¥ |
8.0 mg/dL-9.0 mg/dL | 1.90 (1.10-1.29) [17] | 1.67 (1.51-1.86) [18] | 1.39 (1.21-1.60) |
>9.0 mg/dL | 1.90 (1.10-1.29) [17] | 2.02 (1.76-2.27) [18] | 1.39 (1.21-1.60) |
Utilities | |||
Disease stage utility | 0.71 [24] | 0.61 [24] | |